Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria
A Phase 1b Study to Characterise the Pharmacokinetic/Pharmacodynamic Relationship of Pyronaridine in Healthy Adult Participants Experimentally Infected With Blood Stage Plasmodium Falciparum.
Sponsor: Children's Health Queensland Hospital and Health Service
This PHASE1 trial investigates Malaria and Malaria Recrudescence and is currently completed. Children's Health Queensland Hospital and Health Service leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
May 2025 — Present [monthly]
Completed PHASE1
-
Feb 2025 — May 2025 [monthly]
Completed PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Dec 2022 — Feb 2023 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
May 2022 — Dec 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Health Queensland Hospital and Health Service
- Medicines for Malaria Venture
- QIMR Berghofer Medical Research Institute
- Southern Star Research
- Swiss BioQuant
For direct contact, visit the study record on ClinicalTrials.gov .